Edition:
India

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
20 Jul 2018
Change (% chg)

$0.02 (+1.47%)
Prev Close
$1.36
Open
$1.38
Day's High
$1.38
Day's Low
$1.35
Volume
17,020
Avg. Vol
119,479
52-wk High
$2.65
52-wk Low
$0.69

Chart for

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II... (more)

Overall

Beta: -0.57
Market Cap(Mil.): $17.09
Shares Outstanding(Mil.): 10.75
Dividend: --
Yield (%): --

Financials

  VTGN.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.36 -- --
ROI: -245.77 15.07 14.61
ROE: -415.24 16.60 16.34

BRIEF-VistaGen Therapeutics Reports Qtrly Loss Per Share $‍0.25​

* VISTAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2018 FINANCIAL RESULTS

13 Feb 2018

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder​

* VISTAGEN THERAPEUTICS INC - ‍PREPARES TO INITIATE ITS PHASE 2 STUDY OF AV-101 FOR MAJOR DEPRESSIVE DISORDER​ Source text for Eikon: Further company coverage:

30 Jan 2018

Competitors

Earnings vs. Estimates